Michael C. Dugan, M.D.
Senior Vice President, Chief Medical Officer and Medical Director
Dr. Dugan leads our clinical strategic development as CMO and oversees our CAP accredited CLIA clinical laboratory as Medical Director. He is an experienced physician and biotech executive who has directed several major commercial reference laboratories and helped launch numerous novel molecular diagnostic assays and platforms used in oncology, infectious disease and public health applications such as cancer screening, monitoring, diagnosis and therapy selection. Dr. Dugan has held leadership positions with Clinical Genomics, Exact Sciences, Genzyme Genetics (acquired by LabCorp), Quest Diagnostics (including acquired companies AmeriPath and Specialty Laboratories), and UCLA.
A graduate of the University of Notre Dame (B.S. Biology) and University of Arizona College of Medicine (M.D.), he completed his post-graduate medical education in anatomic pathology at Yale-New Haven Hospital and continued training in pathology and laboratory medicine at Children’s Hospital Los Angeles and UCLA. He is board-certified in Anatomic and Clinical Pathology.
Lyle Arnold, Ph.D.
Dr. Arnold is a biotechnology executive, entrepreneur and developer of innovative technologies covering therapeutics, molecular diagnostics, and genomics. The author of more than 50 scientific publications, he is the principal inventor of the chemiluminescent Hybridization Protection Assay (HPA) and associated technologies. Dr. Arnold holds 36 issued U.S. patents and more than 140 issued and pending patents worldwide. Prior to joining Biocept, Dr. Arnold has worked for various companies in the clinical and diagnostics space, including Aegea Biotechnologies, Gen-Probe, Molecular Biosystems (co-founder), Genta, Synteni, Incyte Genomics, Oasis Biosciences and UCSD Cancer Center.
He received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego.
Julie Mayer, Ph.D.
Vice President, Laboratory Operations
Dr. Mayer adds a wealth of relevant oncology product development and validation experience to the leadership team at Biocept. She has held scientific and management positions at several molecular diagnostics companies, including Navigate BioPharma Services (A Novartis Subsidiary), Genoptix, and Biocept. As a leader in biomarker discovery and the integration of technology, she has developed, validated, and transferred more than 20 Molecular Diagnostic Assays for production and clinical trial testing in multiple CLIA/CAP accredited laboratories.
She holds a M.S. in Experimental and Molecular Pathology and Ph.D in Pathology both from the University of Southern California. Dr. Mayer received her post-doctoral training in Translational Breast Cancer Research at Baylor College of Medicine and in Clinical Cancer Prevention at MD Anderson Cancer Center.
Tony J. Pircher, Ph.D.
Senior Director of Immunochemistry
Dr. Pircher leads the identification and validation of tumor specific markers for the enrichment and detection of rare circulating tumor cells (CTC) and development of predictive and/or prognostic CTC assays. He has extensive experience in developing proteomic and genomic diagnostic assays and is the inventor on several Biocept patents.
He received his Ph.D. in molecular endocrinology from the Karolinska Institute, Stockholm, mentored by Dr. Lars-Arne Haldosen and the world renowned steroid receptor scientist Dr. Jan-Ake Gustafsson. During his postdoctoral training, he worked in the field of molecular hematology at the Pennsylvania State University in the highly prolific research lab of Dr. Don M Wojchowski, where he gained extensive experience in the enrichment of erythroid progenitor cells from blood, bone marrow and spleen.
Beverly Wolgast, Ph.D.
Dr. Wolgast leads our Manufacturing Team. She obtained her B.S. degree in Chemistry from Rensselaer Polytechnic Institute, her Ph.D. Degree from Brandeis, and her Post-Doctoral Fellowship from Harvard University. She has thirty years of industrial experience recently leading Diomics as Chief Operating Officer for 4.5 years, Pacific World Discovery as Director of Chemistry and Operations, and obtaining patents and leadership roles at GNF, Takeda San Diego, Arena Pharmaceuticals, and Celgene.